Related Experiment Video

Updated: Feb 11, 2026

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

15.2K

The current landscape of early drug development for patients with sarcoma in the immunotherapy era

Ana Sebio1, Breelyn A Wilky2, Vicki L Keedy3

  • 1Sarcoma Unit, Royal Marsden Hospital NHS Foundation Trust, Fulham Road, London, SW3 6JJ, UK.

Future Oncology (London, England)
|April 28, 2018
PubMed

Insights

Immunotherapy shows promise for sarcoma treatment, with ongoing trials exploring combinations of immune checkpoint inhibitors and other therapies to improve patient outcomes.

Area of Science:

  • Oncology
  • Immunology

Background:

  • Immunotherapy has revolutionized cancer treatment, particularly for melanoma.
  • Checkpoint inhibition trials in sarcomas have yielded limited success, but specific subtypes show potential.
  • Combining immunotherapies with traditional treatments is a key area of research.

Purpose of the Study:

  • To review preclinical and clinical data supporting immunotherapy in sarcomas.
  • To outline current and future studies investigating immunotherapies for sarcoma patients.

Main Methods:

  • Review of existing preclinical research.
  • Analysis of clinical trial data for immunotherapies in sarcomas.
  • Discussion of emerging immunotherapy strategies.

Main Results:

  • Specific sarcoma subtypes may benefit from current immunotherapies.
  • Combination therapies are being explored to enhance immunogenicity.
  • Numerous clinical trials are actively investigating various immunotherapeutic approaches.

Conclusions:

  • Immunotherapy holds potential for sarcoma treatment.
  • Further research and clinical trials are crucial to establish immunotherapy as a viable option for sarcoma patients.
Keywords:
PD-1PD-L1immunotherapysarcomatreatmenttrials

More Related Videos

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts07:18

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

7.5K
Home-Based Transcranial Direct Current Stimulation Device Development: An Updated Protocol Used at Home in Healthy Subjects and Fibromyalgia Patients11:26

Home-Based Transcranial Direct Current Stimulation Device Development: An Updated Protocol Used at Home in Healthy Subjects and Fibromyalgia Patients

Published on: July 14, 2018

18.0K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
278
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
269
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
277
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
334
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
245